Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Methamphetamine Abstinence in North Louisiana
NCT06899594Phase 1Recruiting
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in methamphetamine use disorder (MUD). Primary endpoints: Participant retention rate at Day 120, Preliminary efficacy of psilocybin on methamphetamine abstinence at Day 120 and 3 more. Started Apr 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT06899594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06899594.